Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

2.

Ten-year predicted coronary heart disease risk in HIV-infected men and women.

Kaplan RC, Kingsley LA, Sharrett AR, Li X, Lazar J, Tien PC, Mack WJ, Cohen MH, Jacobson L, Gange SJ.

Clin Infect Dis. 2007 Oct 15;45(8):1074-81. Epub 2007 Sep 12.

PMID:
17879928
3.

Gender specific correlations of adrenal gland size and body fat distribution: a whole body MRI study.

Ludescher B, Najib A, Baar S, Machann J, Thamer C, Schick F, Buchkremer G, Claussen CD, Eschweiler GW.

Horm Metab Res. 2007 Jul;39(7):515-8.

PMID:
17611905
4.

Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis.

Fisher SD, Miller TL, Lipshultz SE.

Atherosclerosis. 2006 Mar;185(1):1-11. Epub 2005 Nov 16. Review.

PMID:
16297390
5.

Prevalence of elevated cholesterol and associated risk factors among perinatally HIV-infected children (4-19 years old) in Pediatric AIDS Clinical Trials Group 219C.

Farley J, Gona P, Crain M, Cervia J, Oleske J, Seage G, Lindsey J; Pediatric AIDS Clinical Trials Group Study 219C Team.

J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):480-7.

PMID:
15764965
6.

Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children.

Bitnun A, Sochett E, Dick PT, To T, Jefferies C, Babyn P, Forbes J, Read S, King SM.

J Clin Endocrinol Metab. 2005 Jan;90(1):168-74. Epub 2004 Oct 13.

PMID:
15483082
7.

Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.

Taylor P, Worrell C, Steinberg SM, Hazra R, Jankelevich S, Wood LV, Zwerski S, Yarchoan R, Zeichner S.

Pediatrics. 2004 Aug;114(2):e235-42.

PMID:
15286262
8.

Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.

European Paediatric Lipodystrophy Group.

AIDS. 2004 Jul 2;18(10):1443-51.

PMID:
15199321
9.

Combination antiretroviral therapy and the risk of myocardial infarction.

Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El-Sadr WM, Reiss P, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN, Lundgren JD; Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group.

N Engl J Med. 2003 Nov 20;349(21):1993-2003. Erratum in: N Engl J Med. 2004 Feb 26;350(9):955.

10.
11.

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.

Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, King SM.

AIDS. 2003 Jun 13;17(9):1319-27.

PMID:
12799553
12.

Obesity, regional fat distribution, and syndrome X in obese black versus white adolescents: race differential in diabetogenic and atherogenic risk factors.

Bacha F, Saad R, Gungor N, Janosky J, Arslanian SA.

J Clin Endocrinol Metab. 2003 Jun;88(6):2534-40.

PMID:
12788850
13.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
14.

Natural history and risk factors of atherosclerosis in children and youth: the PDAY study.

Zieske AW, Malcom GT, Strong JP.

Pediatr Pathol Mol Med. 2002 Mar-Apr;21(2):213-37. Review.

PMID:
11942537
15.

Maternal and infant factors associated with failure to thrive in children with vertically transmitted human immunodeficiency virus-1 infection: the prospective, P2C2 human immunodeficiency virus multicenter study.

Miller TL, Easley KA, Zhang W, Orav EJ, Bier DM, Luder E, Ting A, Shearer WT, Vargas JH, Lipshultz SE; Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group; National Heart, Lung, and Blood Institute, Bethesda, MD.

Pediatrics. 2001 Dec;108(6):1287-96.

17.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727
18.

Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy.

Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, Demant T.

J Acquir Immune Defic Syndr. 2001 Mar 1;26(3):225-35.

PMID:
11242195
19.

Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy.

Bonnet E, Ruidavets JB, Tuech J, Ferrières J, Collet X, Fauvel J, Massip P, Perret B.

J Clin Endocrinol Metab. 2001 Jan;86(1):296-302.

PMID:
11232015
20.

CDC growth charts: United States.

Kuczmarski RJ, Ogden CL, Grummer-Strawn LM, Flegal KM, Guo SS, Wei R, Mei Z, Curtin LR, Roche AF, Johnson CL.

Adv Data. 2000 Jun 8;(314):1-27.

PMID:
11183293

Supplemental Content

Support Center